“…There were no significant differences in ovipositional delay, egg masses produced, or hatching success between females injected with AhVg-dsRNA constructs versus -lactamase-dsRNA or TE controls. Ovaries harvested from females injected with any of the AhVg-dsRNA treatments did not weigh significantly less than he controls, as a percentage of engorged body weight, nor was there any significant difference in ovarian growth phase (OGP), as defined by Seixas et al (2008). However, average oocyte lengths of AhVg1-dsRNA-(518 ± 15 m) and AhVg1 + 2-dsRNA-injected females (487 ± 22 m) were slightly smaller than that of the combined controls (561 ± 5.2 m; p = 0.015 and p < 0.000 respectively).…”